Journal article
Inter-laboratory validation of nodal/paranodal antibody testing
- Abstract:
-
Background and Aims
Reliable detection of antibodies against nodal targets is vital for the diagnosis of autoimmune nodopathies. The performance characteristics of recently developed in-house assays are unknown. We compared testing at four centres.
Methods
Each submitted 29–40 serum samples to a coordinating centre from one of three groups: (1) autoimmune nodopathy patients, with positive nodal/paranodal antibodies; (2) seronegative patients with other inflammatory neuropathies, and (3) healthy individuals or those with other neurological diseases. The coordinating centre recoded all samples and returned 160 identical aliquots to each testing centre for blinded testing. Once data from all centres had been received by the coordinating centre, unblinded results were returned for analysis. Sensitivity was defined by the proportion of group 1 samples returned as positive. Accuracy was defined as 0.075(sensitivity) + 0.925(specificity).
Results
Centres performed various combinations of ELISA, cell-based (CBAs) and teased-nerve fibre assays. All labs produced highly accurate results (96%–100%) and concordance for the overall result across at least 3 or all 4 test centres was observed for 98% and 89% of the samples respectively. However, 10/30 individual assays (6/14 CBAs and 4/16 ELISAs) were less than 90% sensitive. Only 3 assays had more than 1 false positive result (2 ELISAs and 1 CBA). Combining different assay modalities to produce an overall result did not improve accuracy. Inter-laboratory consistency in the determination of antibody subclasses was poor.
Interpretation
Although most samples were correctly categorised in all 4 centres, the use of a specific test modality or multiple tests did not guarantee accuracy. Early and repeated interlaboratory testing with sharing of samples is important to understand test performance and reproducibility, identify areas for improvement and maintain consistency. To aid this, we provide detailed methods for the best performing tests. Further standardisation of antibody subclass determination is required.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 6.3MB, Terms of use)
-
- Publisher copy:
- 10.1111/jns.70000
Authors
+ Medical Research Council
More from this funder
- Funder identifier:
- https://ror.org/03x94j517
- Grant:
- MR/X003922/1
- MR/P008399/1
- Publisher:
- Wiley
- Journal:
- Journal of the Peripheral Nervous System More from this journal
- Volume:
- 30
- Issue:
- 1
- Article number:
- e70000
- Place of publication:
- United States
- Publication date:
- 2025-01-29
- Acceptance date:
- 2025-01-13
- DOI:
- EISSN:
-
1529-8027
- ISSN:
-
1085-9489
- Pmid:
-
39887819
- Language:
-
English
- Keywords:
- Pubs id:
-
2084729
- Local pid:
-
pubs:2084729
- Deposit date:
-
2025-02-13
- ARK identifier:
Terms of use
- Copyright holder:
- Lleixà et al
- Copyright date:
- 2025
- Rights statement:
- © 2025 The Author(s). Journal of the Peripheral Nervous System published by Wiley Periodicals LLC on behalf of Peripheral Nerve Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record